Mabion S.A., a biotechnology company, engages in the development and implementation of various biotech drugs based on monoclonal antibody technology in Poland.
Moderate growth potential with weak fundamentals.
Share Price & News
How has Mabion's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MAB's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: MAB underperformed the Polish Biotechs industry which returned 61.1% over the past year.
Return vs Market: MAB underperformed the Polish Market which returned -17.9% over the past year.
Price Volatility Vs. Market
How volatile is Mabion's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 months ago | Simply Wall StHow Many Mabion S.A. (WSE:MAB) Shares Do Institutions Own?
7 months ago | Simply Wall StWhat Type Of Shareholder Owns Mabion S.A.'s (WSE:MAB)?
10 months ago | Simply Wall StMabion (WSE:MAB) Shareholders Have Enjoyed A 91% Share Price Gain
Is Mabion undervalued compared to its fair value and its price relative to the market?
Share Price vs. Fair Value
Below Fair Value: MAB (PLN25.45) is trading above our estimate of fair value (PLN25.2)
Significantly Below Fair Value: MAB is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: MAB is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: MAB is unprofitable, so we can't compare its PE Ratio to the Polish market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MAB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MAB has negative assets, so we can't compare its PB Ratio to the PL Biotechs industry average.
How is Mabion forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MAB is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.9%).
Earnings vs Market: MAB is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MAB's is expected to become profitable in the next 3 years.
Revenue vs Market: Insufficient data to determine if MAB's revenue is forecast to grow faster than the Polish market.
High Growth Revenue: Insufficient data to determine if MAB's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MAB's Return on Equity is forecast to be high in 3 years time
How has Mabion performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MAB is currently unprofitable.
Growing Profit Margin: MAB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MAB is unprofitable, and losses have increased over the past 5 years at a rate of -18.5% per year.
Accelerating Growth: Unable to compare MAB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MAB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (17.1%).
Return on Equity
High ROE: MAB's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Mabion's financial position?
Financial Position Analysis
Short Term Liabilities: MAB has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: MAB has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: MAB has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: MAB's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MAB has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: MAB has less than a year of cash runway if free cash flow continues to grow at historical rates of 2.7% each year.
What is Mabion's current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MAB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MAB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MAB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MAB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MAB's dividend in 3 years as they are not forecast to pay a notable one for the Polish market.
How experienced are the management team and are they aligned to shareholders interests?
Mr. Dirk Kreder, PhD serves as the President of the Management Board at Mabion S.A. since March 2020 and serves as its Chief Executive Officer. He also graduated from the International Executive MBA Progr ...
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Mabion S.A.'s company bio, employee growth, exchange listings and data sources
- Name: Mabion S.A.
- Ticker: MAB
- Exchange: WSE
- Founded: 2007
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: zł350.122m
- Shares outstanding: 13.73m
- Website: https://www.mabion.eu
- Mabion S.A.
- gen. Mariana Langiewicza 60 Street
- Konstantynów Lódzki
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|MAB||WSE (Warsaw Stock Exchange)||Yes||Common Bearer Shares||PL||PLN||Aug 2010|
|0QGW||LSE (London Stock Exchange)||Yes||Common Bearer Shares||GB||PLN||Aug 2010|
Mabion S.A., a biotechnology company, engages in the development and implementation of various biotech drugs based on monoclonal antibody technology in Poland. The company is developing various drugs that are used in the treatment of cancer, autoimmune, and metabolic diseases. Its products include MabionCD20, MabionHER2, MabionEGFR, and MabionVEGF that are oncology drugs; and MabionVEGF_Fab drug. The company was founded in 2007 and is based in Konstantynów Lódzki, Poland.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/06/04 11:26|
|End of Day Share Price||2020/06/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.